A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

Phase 2 Completed 40 enrolled Ribomic USA Inc

NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.

Timeline

Start: 2020-11-03
Primary completion: 2021-11-19
Completion: 2021-12-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RBM-007	Aptamer	—	Intravitreal

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

Summary

Timeline

Drugs

Indications